Core Viewpoint - Fangsheng Pharmaceutical announced that its innovative traditional Chinese medicine, Zhilong Tongluo Tablets, has obtained the Phase II clinical research report, demonstrating significant efficacy in treating recovery from cerebral infarction (ischemic stroke) with good safety profile [1] Company Summary - Zhilong Tongluo Tablets are currently the company's exclusive product, with no other enterprises having obtained production approval for this product [1] - The clinical trial results indicate that both high-dose and low-dose groups show comparable efficacy [1] Market Summary - The sales revenue for traditional Chinese medicines treating cerebral infarction, such as Naoxintong Capsules and Tongxinluo Capsules, is projected to be 2.927 billion yuan and 2.273 billion yuan respectively in 2024 [1]

Market Overview - The Shanghai Composite Index closed at 3781.61 points, below the five-day moving average, with a decline of 1.23% [1] - The total trading volume of A-shares reached 171.35 billion yuan [1] Stocks Performance - A total of 119 A-shares broke through the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Chuangyuan Xinke (创远信科) with a deviation rate of 11.34% and a daily increase of 20.09% [1] - Teruid (特锐德) with a deviation rate of 10.64% and a daily increase of 13.85% [1] - Niutai Ge (纽泰格) with a deviation rate of 7.97% and a daily increase of 9.93% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that just crossed the five-day moving average include: - Xinghua New Materials (星华新材) and Haixing Power (海兴电力) [1] - Other stocks with notable performance include: - Ningbo Haiyun (宁波海运) with a daily increase of 9.95% and a deviation rate of 7.96% [1] - Xusheng Group (旭升集团) with a daily increase of 10.03% and a deviation rate of 7.83% [1]

Core Viewpoint - Fangsheng Pharmaceutical's stock price has shown fluctuations, with a year-to-date increase of 12.39% and a recent decline over the past 20 days, indicating mixed market sentiment [2]. Company Overview - Fangsheng Pharmaceutical, established on October 13, 1997, and listed on December 5, 2014, is located in Changsha, Hunan Province. The company specializes in the research, production, and sales of traditional Chinese medicine for cardiovascular, orthopedic, pediatric, and anti-infection treatments [2]. - The company's revenue composition is primarily from product sales (94.62%) and service provision (5.38%) [2]. - As of June 30, 2025, the company had 33,100 shareholders, a slight increase of 0.37% from the previous period, with an average of 13,245 circulating shares per shareholder, down by 0.36% [2]. Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported a revenue of 834 million yuan, a year-on-year decrease of 8.35%. However, the net profit attributable to shareholders increased by 23.67% to 169 million yuan [2]. - The company has distributed a total of 689 million yuan in dividends since its A-share listing, with 484 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the top three circulating shareholders include ICBC Medical Health Stock (000831) with 5.40 million shares, unchanged from the previous period, and Rongtong Health Industry Flexible Allocation Mixed A/B (000727) with 5.00 million shares, which increased by 500,000 shares [3]. - Notably, E Fund Healthcare Industry Mixed A (110023) and Anxin Pharmaceutical Health Stock A (010709) have exited the top ten circulating shareholders list [3].

Core Viewpoint - Fangsheng Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.09% on September 19, 2023, reflecting a total market value of 4.742 billion yuan and a year-to-date increase of 7.89% [1] Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported operating revenue of 834 million yuan, a year-on-year decrease of 8.35%, while net profit attributable to shareholders increased by 23.67% to 169 million yuan [2] - The company has distributed a total of 689 million yuan in dividends since its A-share listing, with 484 million yuan distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 33,100, with an average of 13,245 circulating shares per person, a slight decrease of 0.36% [2] - The top three circulating shareholders include Industrial Bank Medical Care Stock, holding 5.3997 million shares, and Rongtong Health Industry Flexible Allocation Mixed A/B, which increased its holdings by 500,000 shares to 5 million [3]

Core Viewpoint - Fangsheng Pharmaceutical's stock has shown mixed performance in recent trading, with a year-to-date increase of 13.69% but a recent decline over the past 20 days of 9.11% [2] Group 1: Stock Performance - As of September 18, Fangsheng Pharmaceutical's stock price rose by 2.25% to 11.38 CNY per share, with a trading volume of 1.29 billion CNY and a turnover rate of 2.64%, resulting in a total market capitalization of 4.997 billion CNY [1] - The stock has increased by 2.61% over the last five trading days and by 18.42% over the last 60 days [2] Group 2: Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported operating revenue of 834 million CNY, a year-on-year decrease of 8.35%, while the net profit attributable to shareholders increased by 23.67% to 169 million CNY [2] - The company has distributed a total of 689 million CNY in dividends since its A-share listing, with 484 million CNY distributed over the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Fangsheng Pharmaceutical was 33,100, an increase of 0.37% from the previous period, with an average of 13,245 circulating shares per shareholder, a decrease of 0.36% [2] - The top three circulating shareholders include Industrial Bank Medical Health Stock, holding 5.3997 million shares, and Rongtong Health Industry Flexible Allocation Mixed A/B, which increased its holdings by 500,000 shares to 5 million [3]

证券代码：603998 证券简称：方盛制药 公告编号：2025-080 湖南方盛制药股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 每股分配比例 A股每股现金红利0.15元 一、通过分配方案的股东会届次和日期 （1）无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统向股权登记日上海证券交 易所收市后登记在册并在上海证券交易所各会员办理了指定交易的股东派发。已办理指定交易的投资者 可于红利发放日在其指定的证券营业部领取现金红利，未办理指定交易的股东红利暂由中国结算上海分 公司保管，待办理指定交易后再进行派发。 本次利润分配方案经公司2025年5月20日的2024年年度股东大会审议通过，授权董事会办理中期利润分 配相关事宜，并经公司2025年8月27日召开第六届董事会第三次会议审议通过。 二、分配方案 1.发放年度：2025年半年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上 ...

证券日报网讯 9月11日晚间，方盛制药发布公告称，2025年半年度利润分配方案为A股每股现金红利 0.15元（含税），股权登记日为2025年9月17日，除权（息）日及现金红利发放日均为2025年9月18日。 （文章来源：证券日报） ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-081 湖南方盛制药股份有限公司 关于参加 2025 年湖南辖区上市公司投资者网上集体 接待日暨半年度业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，湖南方盛制药股份有限 公司（以下简称"公司"）将参加由湖南证监局、湖南省上市公 司协会与深圳市全景网络有限公司联合举办的"资本聚三湘 楚 光耀新程——2025 年湖南辖区上市公司投资者网上集体接待日 暨半年度业绩说明会"活动，现将相关事项公告如下： 湖南方盛制药股份有限公司董事会 2025年9月12日 第 1 页，共 1 页 本次活动将采用网络远程的方式举行，投资者可登录"全景 路演"网站（https://rs.p5w.net），或关注微信公众号：全景财经， 或下载全景路演 APP，参与本次互动交流，活动时间为 2025 年 9 月 19 日（星期五）14:0 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-080 湖南方盛制药股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/9/17 | － | 2025/9/18 | 2025/9/18 | 差异化分红送转：否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 20 日的2024年年度股东 大会审议通过，授权董事会办理中期利润分配相关事宜，并经公 司 2025 年 8 月 27 日召开第六届董事会第三次会议审议通过。 二、 分配方案 1.发放年度：2025年半年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登 记 ...

Core Insights - The stock price of Fangsheng Pharmaceutical has decreased by 2.01% on September 9, trading at 11.21 CNY per share with a market capitalization of 4.922 billion CNY [1] - The company has experienced a year-to-date stock price increase of 10.33%, but has seen a decline of 2.94% over the last five trading days [1] Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported a revenue of 834 million CNY, a year-on-year decrease of 8.35%, while the net profit attributable to shareholders increased by 23.67% to 169 million CNY [2] - Cumulative cash dividends since the company's A-share listing amount to 623 million CNY, with 418 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders has increased to 33,100, with an average of 13,245 circulating shares per shareholder, a slight decrease of 0.36% [2] - The top three circulating shareholders include ICBC Medical Health Stock, holding 5.3997 million shares, and Rongtong Health Industry Flexible Allocation Mixed Fund, which increased its holdings by 500,000 shares to 5 million [3]